Benzinga

SEPTEMBER 21, 2023

OTC: SRNEQ , "Sorrento")). (OTC: OTC: SRNEQ , "Sorrento")). million; plus (iii) a credit bid of all amounts owed to Scilex under the junior secured debtor-in-possession financing facility provided by Scilex to Sorrento. PALO ALTO, Calif., million of such warrants), each with an exercise price of $0.01

Finance 40

Finance 40

Benzinga

NOVEMBER 10, 2022

Sorrento owns over 96% of Scilex. 10, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ: SCLX ), a majority-owned subsidiary of Sorrento Therapeutics, Inc. Executive Chairman of Scilex and Chairman and Chief Executive Officer of Sorrento. About Scilex Holding Company.

Marketability 40

Marketability Equity 40

Law 360 M&A

FEBRUARY 22, 2024

Sorrento Therapeutics Inc. told a Texas bankruptcy court the company's choice to bring a Chapter 11 in the Lone Star state was sound, so the court should ignore a call from the U.S. Trustee's Office to trash or relocate the case.

97

97

Benzinga

OCTOBER 31, 2022

Post-closing company will be renamed "Scilex Holding Company" upon closing of the Business Combination, with common stock and warrants expected to trade on the Nasdaq Capital Market under the new ticker symbols "SCLX" and "SCLXW", respectively. majority-owned subsidiary of Sorrento Therapeutics, Inc.)

Marketability 40

Marketability 40

Benzinga

APRIL 4, 2022

April 04, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. Scilex Holding Company and Vickers Vantage Corp. About Scilex Holding Company. About Sorrento Therapeutics, Inc. PALO ALTO, Calif.,

Marketability 40

Marketability 40

Law 360 M&A

MARCH 4, 2024

Creditors for drug developer Sorrento Therapeutics Inc. have asked a Texas bankruptcy judge to keep the company's Chapter 11 case in the Lone Star State, saying the U.S. trustee's bid to move it comes too late and wouldn't help those hoping for recoveries.

40

40

Law 360 M&A

OCTOBER 11, 2023

Sorrento Therapeutics Inc. has asked a Texas bankruptcy judge to approve a sale of its stake in a joint venture with pharmaceutical company Yuhan Corp. to the South Korean firm for $20 million, citing an immediate need for liquidity to cover Chapter 11 expenses.

40

40